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The first goal is to identify changes in mRNA in blood cells and in serum glycoprotein concentrations that are induced by prion infection in mice. A prion-specific signature would form the basis for a blood-based screen for prion infected individuals. Using DNA microarrays, we have determined that expression profiling can distinguish clinically ill prion-infected mice from their corresponding controls. A novel mass spectrometry-based proteomics technology has been optimized to identify quantitative changes in serum glycoproteins resulting from prion infection. The second goal is to determine whether CNS stem cells can provide an in vitro model for prion infection. CNS stem cell lines have been established from six different lines of mice. These cell lines express prion protein and at least one is capable of replicating the misfolded PrPsc isoform. These studies could lead to the development of an in vitro system to assess the infectivity of prions in human cells. whether there are expression profiles unique to each host-agent combination and/or whether a genotype-independent and agent-independent profile specific to prion exposure can be detected. Each timepoint will consist of 4 replicates per group. (Months 6-36) In Progress. e. Changes in mRNA expression suggestive of specificity for prion infection will be reevaluated using larger volumes of blood pooled from relevant groups of mice. Up to 200 mice will be available for this purpose. (Months 12-36) In Progress. We have also decided to examine changes in blood white cell populations with time after infection by flow cytofluorimetry. We also are piloting preparing RNA from enriched populations of peripheral blood cells to detect changes that would be masked in the mixed population.
Task 2. We have demonstrated by several techniques that mouse CNS stem cell or neurosphere cultures express levels of PrPC comparable to those of the infectible N2A cell line. We have extended these studies beyond using the existing cell lines proposed in the application to creating CNS stem cell cultures from different strains of mice and from transgenic mice expressing high levels of PrPc. Cell lines from Tg4053 mice, which express high levels of mouse PrP, can be infected and replicate scrapie prions. This result is very exciting and indicates the feasibility of developing sensitive assays for infectious prions from other animals including human, cow, deer, and elk using cell lines from transgenic mice expressing PrP transgenes from these species. Preliminary results using cell lines from non-transgenic mice also are encouraging and suggest that prions can replicate in CNS stem cells expressing normal levels of PrP. This would provide the opportunity to use cell lines derived from various species to directly test prion susceptibility.
KEY RESEARCH ACCOMPLISHMENTS "• Optimized RNA isolation to ensure reproducibility on microarrays "• Ran and analyzed over 140 peripheral blood RNA samples for differential gene expression "• Demonstrated differential gene expression in peripheral blood of clinically ill mice "• Optimized procedure for analysis of differential expression of plasma glycoproteins and began time course studies "• Demonstrated differences in glycoproteins in plasma of clinically ill mice "• Established CNS stem cell cultures from fetal brain of six different lines of mice "* Demonstrated that CNS stem cell cultures express PrPc "• Demonstrated production of PrPsc in a CNS stem cell line from a transgenic mouse expressing high levels of PrP, indicating the potential for a tissue culture assay for infectious prions.
REPORTABLE OUTCOMES
In addition to the cell lines outlined above, two abstracts have resulted from research supported by this award. The abstracts are included with this report.
CONCLUSIONS
Based on our results to date, we are confident that when the study is complete we will be able to conclude whether there are signature differences in gene expression or plasma glycoproteins in presymptomatic, prion-infected animals that can be used to identify prion infected individuals.
Our most exciting result is that mouse CNS stem cell cultures appear to replicate scrapie prions and have potential as an assay for infectious particles.
APPENDICES
Two abstracts from the 9' International Conference on Alzheimer's Disease and Related Disorders are attached.
Background: Although the most dramatic control of prion incubation time in the mouse is exerted by alternative alleles of the prion protein (PrP) gene, other loci strongly influence the length of the interval between prion inoculation and onset of disease. Crosses between CAST/Ei and SJL/J mice, which share PrP gene coding sequences but differ in incubation time, and quantitative trait analysis were used to identify to regions on Chromosomes 9 and 11 that harbor prion incubation time modifier genes. Objective: The goal is to identify the genes within these chromosomal intervals that underlie differential prion susceptibility. Method: Differences in activity of allelic gene products are responsible for the majority of quantitative trait loci and some activity differences may reflect level of mRNA expression. SJL strains congenic for either the Chromosome 9 or Chromosome 11 interval from long incubation time CAST mice were produced by backcrossing and marker-assisted selection. Microarray analysis is used to compare gene expression in brains and spleens of scrapie prion-infected and non-infected congenic pairs. Differentially expressed genes mapping within the congenic intervals or active in pathways involving genes in these intervals are modifier gene candidates. The scrapieinfected neuroblastoma cell line ScN2a provides a substrate to test whether lowering expression of a candidate gene reduces production of the disease-specific PrPsc isoform. Results: The effectiveness of RNA interference (RNAi) was demonstrated by the ability of anti-PrP constructs expressing fluorescent protein as an indicator of transformation and a hairpin substrate for production of small inhibitory RNAs to suppress expression of PrP as detected by immunofluorescence. Such RNAi Sc http://www~abstractsonlineom/submit/SubmilPrinterFriendlyVersionasp?ContT Kcy=%78353F58CE`/`2D97DA`/`2D4382*/`2DBB84%2DC7F6D64B92 ...
